Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide in Hepatic Impairment
NCT02016911Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2013
- Primary completion
- Jan 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 1, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the semaglutide plasma concentration curve. Started Dec 2013; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02016911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02016911.